Phase 1b/2 study of capmatinib plus gefitinib in patients with EGFR-mutated, MET-dysregulated non-small cell lung cancer who received prior therapy: Final overall survival and safety.
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Sun Yat-sen University Cancer Center, Seoul National University Hospital, Chinese PLA General Hospital, Asan Medical Center, University of Ulsan, National Taiwan University, Samsung Medical Center, Universitair Ziekenhuis Leuven, KU Leuven, National Cheng Kung University Hospital, Vall d'Hebron Hospital Universitari, Novartis (Switzerland), National Cancer Centre Singapore
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Novartis
OpenAlex ID: W3171645838